Mercedes Fernandez- Arevalo

Prof. Mercedes Fernandez- Arevalo

Auto-generated profile, based on publicly available information

Prof. Mercedes Fernandez- Arevalo


Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2008 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MHM.A. Holgado
M.A. Holgado
José Luis Arias MedianoJosé Luis Arias Mediano
José Luis Arias Mediano
MCM.J. Cózar
M.J. Cózar
JAJ. Alvarez-Fuentes
J. Alvarez-Fuentes
AGAlfonso Miguel Ganan-Calvo
Alfonso Miguel Ganan-Calvo
MFM. Fernández-Arévalo
M. Fernández-Arévalo

1 July 1993 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Isidoro CaraballoIsidoro Caraballo
Isidoro Caraballo
MFM. Fernández-Arévalo
M. Fernández-Arévalo
MHM.A. Holgado
M.A. Holgado
Antonio M. Rabasco-AlvarezAntonio M. Rabasco-Alvarez
Antonio M. Rabasco-Alvarez

1 April 2002 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
CSCarla Sánchez-Lafuente
Carla Sánchez-Lafuente
SFSandra Furlanetto
Sandra Furlanetto
MFMercedes Fernández-Arévalo
Mercedes Fernández-Arévalo
JAJosefa Alvarez-Fuentes
Josefa Alvarez-Fuentes
Antonio M. Rabasco-AlvarezAntonio M. Rabasco-Alvarez
Antonio M. Rabasco-Alvarez
Paola Angela MuraPaola Angela Mura
Paola Angela Mura

30 January 2015 in Journal of Nanoparticle Research
Verified
Journal Article
Closed access
PDF file
MDMatilde Durán-Lobato
Matilde Durán-Lobato
LMLucía Martín
Lucía Martín
Luís Miguel GoncalvesLuís Miguel Goncalves
Luís Miguel Goncalves
MFMercedes Fernández-Arévalo
Mercedes Fernández-Arévalo
AAAntonio Almeida
Antonio Almeida

1 June 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
LMLucía Martín
Lucía Martín
IMI. Muñoz-Rubio
I. Muñoz-Rubio
JPJose Prados
Jose Prados
JÁJ. Álvarez-Fuentes
J. Álvarez-Fuentes
JMJOSÉ MANUEL CALDERÓN MONTAÑO
JOSÉ MANUEL CALDERÓN MONTAÑO
MFM. Fernández-Arévalo
M. Fernández-Arévalo

1 June 2014 in Journal of Biomedical Nanotechnology
Verified
Journal Article
Closed access
MDMatilde Durán-Lobato
Matilde Durán-Lobato
IMInmaculada Muñoz-Rubio
Inmaculada Muñoz-Rubio
MHM. Ángeles Holgado
M. Ángeles Holgado
JÁJosefa Álvarez-Fuentes
Josefa Álvarez-Fuentes
MFMercedes Fernández-Arévalo
Mercedes Fernández-Arévalo
LMLucía Martín-Banderas
Lucía Martín-Banderas
This article aimed to produce, characterize and evaluate different surface-modified naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (CB13) loaded poly(lactic-co-glycolic acid) nanoparticles in order to improve their oral absorption and in vivo biodistribution. Plain and surface-modified PLGA nanoparticles were successfully prepared using a nanoprecipitation method. Chitosan, Eudragit® RS, lecithin and vitamin E were used as surface modifying agents. The NPs were evaluated in terms of mean diameter and size distribution, zeta potential, morphology, drug loading, drug release profiles, mucoadhesive properties, in vitro cell viability and uptake and in vivo biodistribution. Mean particle size distributions in the range of 253–344 nm, spherical shape and controlled zeta potential values were observed depending on the additive employed. High values of entrapment efficiency were obtained for all the formulations. Lecithin and vitamin E modified particles showed higher release rates when compared to the rest of formulations. A clear improvement in ex vivo mucoadhesion properties was observed in the case of chitosan- and Eudragit® RS-modified nanoparticles. Chitosan-poly(lactic-co-glycolic acid) nanoparticles showed the highest uptake values on Caco-2 cells. Biodistribution assays proved that most of the particles were accumulated in liver and spleen. An important goal has been achieved in this investigation: CB13, a highly lipophilic drug with low water solubility, can reach the interior of cells more efficiently when it is included in these surface-modified polymeric carriers.